

Original Research Article

EFFECTS OF TOLTERODINE ON DEPRESSION, ANXIETY, LEARNING AND MEMORY IN MICE

Mehmet Hanifi TANYERI^a, Mehmet Emin BUYUKOKUROGLU^b, Pelin TANYERI^{b,*}, Oguz MUTLU^c, Rumeysa KELES KAYA^b, Aykut OZTURK^b, Şeyma Nur BASARIR BOZKURT^b, Dilara ORMANCI^b

^a*Yenikent Government Hospital, Department of Urology, Cahit Kirac street, 54290, Adapazarı, Sakarya-Turkey*

^b*Sakarya University, Faculty of Medicine, Department of Pharmacology, Konuralp street, number:81, 54290, Adapazarı, Sakarya-Turkey*

^c*Kocaeli University, Faculty of Medicine, Department of Pharmacology, Umuttepe street, number:515, 41001, İzmit, Kocaeli-Turkey*

ABSTRACT

Background: Overactive bladder (OAB) is characterized by urinary symptoms such as frequent urination, urgency, urinary incontinence, and nocturia. Tolterodine is a drug specially developed for the treatment of overactive bladder. The aim of present study is to evaluate the effects of tolterodine on depression, anxiety, learning and memory to understand if tolterodine may be effective in OAB caused mood and cognitive disorders.

Methodology:

Study design: All the drugs were given intraperitoneally (i.p.), 30 min before the experiment. Here, we investigated the effects of tolterodine (0.3, 1, 3 mg/kg) on depression, anxiety, learning and memory by using forced swimming test, elevated plus maze test, passive avoidance, and Morris water maze, respectively in mice. Locomotor activity was evaluated by open field test.

Place and Duration of Study: Department of Pharmacology and Department of Urology, Sakarya University, Animal Research Center, between August 2019 and September 2020.

Results: All doses of tolterodine dose-dependently reduced immobility time, compared to saline group. Tolterodine (1, 3 mg/kg) prolonged the time spent in open arms compared to saline group. Tolterodine (3 mg/kg) significantly increased the number of entries into the open arms. Tolterodine had no effect on learning and memory performance of normal mice;

however, tolterodine (3 mg/kg) significantly ameliorated learning and memory disruption induced by scopolamine.

Conclusion: Our results demonstrate that tolterodine prevented experimentally induced depression and anxiety, improved memory and learning of naive animals, and reversed memory and learning impairment with scopolamine. Further preclinical and clinical studies with tolterodine should be done to support all these hypothesis and patients with OAB who need antidepressant and anxiolytic therapy may be treated with single drug instead of more than one drug in the future.

Keywords: Tolterodine; learning; memory; anxiety; depression; overactive bladder

1. INTRODUCTION

Overactive bladder is characterized by urinary symptoms such as frequent urination, urgency, urinary incontinence, and nocturia as a result of excessive contraction of the detrusor during bladder filling. These contractions are mostly under the control of the parasympathetic system [1,2,3]. Antimuscarinic drugs suppress the contraction of the detrusor by preventing acetylcholine from binding to muscarinic receptors [4,5].

Antimuscarinic drugs are used in the first step at the accommodation. Antimuscarinic drugs exert a muscarinic blocking effect on the detrusor muscle [6]. There are 5 types of muscarinic receptors. M3 receptors are responsible for the contractions of the detrusor muscle [7,8]. Also, muscarinic receptors are found in the central nervous system other than the bladder; plays an important role in learning and memory [7,9].

The first antimuscarinic drug used in overactive bladder was oxybutynin. However, oxybutynin has side effects such as dry mouth and constipation that limit its clinical use [10]. These side effects are less common with the use of second generation antimuscarinic agents such as tolterodine [11]. Tolterodine is a drug specially developed for the treatment of overactive bladder; have more specific effects on M3 receptors [12].

Use of medicines in an unapproved indication, age group, dose or administration route is defined as off-label drug use. Off label drug use provides new opportunities for existing approved drugs, and reduces the time and cost involved in drug discovery. Muscarinic receptors are also found in the central nervous system other than the bladder; based on this information we want to understand if tolterodine may be effective in OAB caused mood and cognitive disorders.

Depression and anxiety are associated with OAB; can affect their life qualities. With all these background, we investigated the effects of antimuscarinic drug tolterodine on depression in forced swimming and on anxiety in elevated plus maze test in mice and also imipramine as positive control for depression, and diazepam as positive control for anxiety. Besides these, we investigated the effects of antimuscarinic drug tolterodine on learning in passive avoidance and on memory in morris water maze test in mice and also on learning and memory in scopolamine-treated mice, which is used as model showing deficits in cognitive performance.

2. METHODOLOGY

2.1 Animals

Male inbred BALB/c ByJ mice (Animal Research Center, Sakarya-Turkey) aged 7 weeks upon arrival to the laboratory were used in this study. Female animals mostly don't be used

in behavioral tests because they have menstrual cycle which may cause false positive or negative results. For this reason, we used male animals similar to our previous studies [13,14]. Animals (4–5 per cage) were kept in the laboratory at 21 ± 1.5 °C with 60% relative humidity under a 12 h light/dark cycle (light on at 8.00 p.m.). Tap water and food pellets were available ad libitum. All experiments were performed between 10.00 and 12:00 a.m. All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the appropriate ethics committee. Ethical approval was granted by the Sakarya University Ethics Committee (04.04.2018, Number = 12, Sakarya/Turkey).

2.2. Drugs

Tolterodine, imipramine hydrochloride, diazepam and scopolamine were purchased from Sigma Chemicals (St Louis, Mo, USA). Drugs were dissolved in saline. Saline (%0.9) was used as the vehicle controls. All the drugs were given intraperitoneally (i.p.) in a volume of 0.1 ml per 10 g body weight of mice. The doses were chosen based on previous behavioural studies [13,14]. Drugs were prepared freshly on the day of experiment.

2.3. Experimental Design

We investigated the effects of tolterodine on depression, anxiety, learning and memory by using forced swimming test, elevated plus maze test, passive avoidance and morris water maze, respectively, in mice. Additionally, the locomotor activity was evaluated by measuring the total distance traveled in the open field test.

Schematic Design of Experiments:

TESTS/ GROUPS	FST (Forced Swimming Test)	EPM (Elevated Plus Maze)	PA (Passive Avoidance)	MWM (Morris Water Maze)	LA (Locomotor Activity)
Saline %0.09	N=8	N=8	N=8	N=8	N=8
Imipramin 30	N=8				N=8
Diazepam 2		N=8			N=8
Scopolamine 0.6			N=8	N=8	N=8
Tolterodine 0.3	N=8	N=8	N=8	N=8	N=8
Tolterodine 1	N=8	N=8	N=8	N=8	N=8
Tolterodine 3	N=8	N=8	N=8	N=8	N=8
Scop 0.6+tol 3			N=8	N=8	N=8

2.3.1 Forced swimming test (FST)

The mice were dropped individually into plexiglas cylinders (height 25 cm, diameter 10 cm) containing 10 cm of water maintained at 23-25°C and left there for 6 min. The duration of immobility (in seconds) was recorded during the last 4 min of the 6-min testing period. The absence of hind leg movement was recorded as immobility by stopwatch cumulation by a single observer who was aware of the treatments during the exposures.

Forty male inbred BALB/c ByJ mice were used in the Forced Swimming Test. Mice were randomly divided into experimental groups (n=8 mice): saline, imipramine 30 mg/kg (Imp), tolterodine 0.3, 1 and 3 mg/kg, respectively. All experiments were performed between 10.00 and 12:00 a.m. All drugs or saline were given 30 min before the experiment.

2.3.2 Elevated Plus-Maze (EPM) Test

Anxiety-related behavior was measured by the EPM test. The experiments were conducted in a dimly lit, semi-soundproof room, illuminated with table lamp (80 lux). Maze was made of wood and consisted of two open (29 cm long x 5 cm wide) and closed arms (29 cm x 5 cm with 15 cm high walls) forming a square cross with a 5 cm square center piece. In order to avoid falls the open arms was surrounded by a short (1 cm) plexiglass edge. The maze was elevated 40 cm above the floor. The open arms and central platform were painted white and enclosed arms were painted black.

Each mouse was placed at the center of the maze facing one of the open arms and allowed to explore the maze. During a 5-min test period, the number of entries into both open and enclosed arms of the maze (defined as the entry of all four limbs into the arms) and the time spent in the open arms was recorded. The observer was present always in the same position towards to the open arms and behind the animals. The open arm activity was evaluated as the following: 1) time spent in the open arms relative to the total time spent in the plus-maze (300 s), expressed as a percentage; 2) number of entries into the open arms relative to the total number of entries into both the open and closed arms, expressed as a percentage. These values were used as indices of anxiety in mice. Any animal that fell off the maze was excluded from the experiment.

Elevated plus-maze is one of the tests used to evaluate anxiety in animals. In the normal cases, the animals prefer to stay within the closed arms instead of open arms owing to feel more safe. Drugs with anxiolytic properties increase the time spent on the open arm. As the values for both of the measured parameters changed in the same direction compared to control values (i.e., if both the time spent in the open arms and the number of open arm entries was increased or if both were decreased) and the change in one of the parameters was statistically significant, then an effect on anxiety was considered to have occurred. The time spent in the open arms and the numbers of open arm entries were always observed to change in the same direction.

Thirty-eight male inbred BALB/c ByJ mice were used in the study. Mice were randomly divided into experimental groups in EPM: saline, diazepam 2 mg/kg (Dzm), tolt 0.3 mg/kg, tolt 1 mg/kg and tolt 3 mg/kg. Each experimental group consisted of 7-8 mice. All experiments were performed between 10.00 and 12:00 a.m. All drugs or saline were given 30 min before the experiment.

2.3.3. Passive Avoidance (PA) test

Animals were trained in a one-trial, step-through PA apparatus to evaluate memory based on contextual fear conditioning and instrumental learning. A decrease in retention latency indicates an impairment in memory in the PA task. The apparatus consisted of a box with an

illuminated part (L 7 × 12.5 × h 14 cm) and a dark part (L 24 × 12.5 × h 14 cm), both equipped with a grid floor composed of steel bars (0.3 cm diameter) spaced 0.9 cm apart. The inhibitory avoidance task consisted of two trials. On the first day of training, the mice were individually placed into the light compartment and allowed to explore the boxes. The intercompartment door was opened after a 10 second acclimation period. In the acquisition trial, each mouse was placed in the illuminated compartment, which was lit by a bright bulb (2000 lux). If the mouse stepped into the dark compartment (2/3 of the tail in the dark compartment), the door was closed by the experimenter, and an inescapable foot shock (0.3 mA/1 second) was delivered through the grid floor of the dark compartment. A cut-off time of five minutes was selected. The time taken to enter the dark compartment (training latency) was recorded. Immediately after the shock, the mouse was returned to the home cage. The retention trial started 24 hours after the end of the acquisition trial. The animals received drugs prior to retention training. Each mouse was placed in the illuminated compartment as in the training trial. The door was opened after a 10 second acclimation period. The step-through

Latency in the retention trial (with a maximum 300 seconds cut-off time) was used as the index of retention of the learned experience. A shock was not applied during the retention trial.

Forty eight male inbred BALB/c ByJ mice were used in the study. Mice were randomly divided into experimental groups in PA test: saline; scopolamine 0,6 mg/kg (Scop), tolt 0.3 mg/kg, tolt 1 mg/kg, tolt 3 mg/kg and Scop+tolt 3 mg/kg. Each experimental group consisted of 8 mice. All experiments were performed between 10.00 and 12:00 a.m.. All drugs or saline were given 30 min before the experiment.

2.3.4. Morris Water Maze (MWM) test

The MWM comprised a circular pool (90 cm diameter) filled with water (22°C) and rendered opaque by addition of small black balls. The pool was located in a dimly lit, soundproof test room with various visual cues, including a white/ black colored poster on the wall, a halogen lamp, a camera, and the experimenter. The maze was divided into four quadrants, and three equally spaced points served as starting positions around the edge of the pool. The order of the release positions was varied systematically throughout the experiment. A circular escape platform (6 cm diameter and 12 cm high) was located in one quadrant 1 cm above the water surface during the familiarization session and 1 cm below the water surface during the other sessions. Video tracking was conducted with a video camera focused on the full diameter of the pool. Navigation parameters were analyzed using the Ethovision 8.5 video analysis system (Noldus Ethovision XT). Mice were trained in MWM five times per day (familiarization session, S1, S2, S3, and S4). One familiarization and four acquisition sessions were carried out using the MWM. During the familiarization session and acquisition phase of experiment, each mouse underwent three trials. The delay between trials was 60 seconds, and a 1-day interval was used between each session. For each trial, the mouse was removed from the home cage and placed in the water maze at one of three randomly determined locations with its head facing the center of the water maze. After the mouse had found and climbed onto the platform, the trial was terminated, and the escape latency was recorded. If the mouse did not climb onto the platform in 60 seconds, the trial was terminated, and experimenter guided the mouse to the platform; an escape latency of 60 seconds was recorded. Twenty-four hours after the final acquisition session, a “probe trial” was used to assess the spatial memory retention of the location of the hidden platform. During this trial, the platform was removed from the maze and the mouse was allowed to search the pool for 60 seconds. The percent of time spent in each quadrant was recorded.

Forty-eight male inbred BALB/c ByJ mice were used in the study. Mice were randomly divided into experimental groups in MWM test: saline; scopolamine 0,6 mg/kg; tolterodine 0.3 mg/kg; tolterodine 1 mg/kg; tolterodine 3 mg/kg; scopolamine 0,6 mg/kg+tolterodine 3 mg/kg. Each experimental group consisted of 8 mice. All experiments were performed between 10.00 and 12:00 a.m. All drugs or saline were given 30 min before the probe trial of MWM test.

2.3.5 Open field test

Since compounds altering motor activity may give false positive/negative effects in FST, elevated plus maze test, passive avoidance test and Morris water maze test, spontaneous locomotor activity of mice was evaluated by monitoring the activity of the animals in an open field. The animals were placed in the center of the apparatus and behaviors were recorded for a period of 5 min using the Ethovision-XT video tracking system. The locomotor activity was evaluated by measuring the total distance traveled in the apparatus and the speed of the animals.

2.3. Statistics

All data were expressed as mean \pm standard error of mean (SEM). Statistical analysis was performed using GraphPad Prism 6.0® software (GraphPad Software, Inc., San Diego, CA). Groups of data were compared with one-way analysis of variance (ANOVA) and Tukey post-hoc test. Values were considered significantly different at $p < 0.05$.

3. RESULTS

3.1. Forced Swimming Test

One-way ANOVA posthoc Tukey test showed a significant effect of tolterodine and imipramine treatment upon immobility time in FST [F (40,4) =38,402, $p < 0.0001$]. Post-hoc comparisons revealed that imipramine ($p < 0.001$) and tolterodine (0.3, 1 and 3 mg/kg) dose dependently reduced immobility time, compared to saline group ($p < 0.01$, $p < 0.001$, $p < 0.001$; respectively, Fig. 1).




Fig. 1. Immobility time (seconds) in the forced swim test (n=8)

***: $p < 0.001$ compared to Saline group, by ANOVA (Tukey test), **: $p < 0.01$ compared to Saline group, by ANOVA (Tukey test)

Mean \pm S.E.M = Mean values \pm Standard error of means

Table 1: Immobility time (in seconds) in the forced swim test. (n=8)

$p < 0.001$ compared to Saline group, by ANOVA (Tukey test),

$p < 0.01$ compared to Saline group, by ANOVA (Tukey test)

Mean \pm S.E.M = Mean values \pm Standard error of means

Drugs	Immobility time (s) Mean \pm S.E.M	Number of mice	p value
Saline	199.2 \pm 8.19	8	
Imip 30 mg/kg	122 \pm 9.53	8	$p < 0.001$ (saline & imip)
Tolt 0.3 mg/kg	141.25 \pm 16.03	8	$p < 0.01$ (saline & tolt 0.3)
Tolt 1 mg/kg	66.62 \pm 10.96	8	$p < 0.001$ (saline & tolt 1)

Tolt 3 mg/kg	25.25±9.21	8	p<0.001 (saline & tolt 3)
--------------	------------	---	---------------------------

3.2 Elevated Plus Maze Test

One-way ANOVA posthoc Tukey test showed a significant effect of drug treatment upon the time spent in open arms in EPM test [F (37,4) =13,634, p<0.0001; Fig. 2a]. Post-hoc comparisons revealed that diazepam (2 mg/kg) significantly increased the time spent in open arms compared to saline group (p<0.001). Tolterodine (0.3 mg/kg) did not have any effect on time spent in open arms while tolterodine (1 and 3 mg/kg) prolonged the time spent in open arms (p< 0.05) (Fig 2a).

One-way ANOVA posthoc Tukey test displayed an important effect of drug treatment upon the number of entries to the open arms in EPM test [F(37,4)=21,546, p<0.0001; Fig. 2b]. Post-hoc comparisons revealed that diazepam (2 mg/kg) significantly increased the number of entries to the open arms compared to saline group (p<0.001) and also tolterodine (3 mg/kg) increased the number of entries into the open arms (p< 0.05) (Fig 2b). However, Tolterodine (0.3 and 1 mg/kg) did not have any effect on the number of entries in open arms.




Fig. 2a. Percentage of time spent in the open arms (2a) in elevated plus-maze test. (n=8)

***: p<0.001 compared to Saline group, by ANOVA (Tukey test), *: p<0.05 compared to Saline group, by ANOVA (Tukey test)

Mean ± S.E.M = Mean values ± Standard error of means

Table 2a: Percentage of time spent in the open arms. (n=8)

p<0.001 compared to Saline group, by ANOVA (Tukey test),

p<0.05 compared to Saline group, by ANOVA (Tukey test)
 Mean ± S.E.M = Mean values ± Standard error of means

Drugs	Percentage of time spent in the open arms (%) Mean ± S.E.M	Number of mice	p value
Saline	20.14±1.15	8	
Diaze 2 mg/kg	70.87±2.66	8	<i>p</i> <0.001 (saline & diaze)
Tolt 0.3 mg/kg	25.52±5.03	8	<i>p</i> >0.05 (saline & tolt 0.3)
Tolt 1 mg/kg	36.65±6.25	8	<i>p</i> <0.05 (saline & tolt 1)
Tolt 3 mg/kg	44.23±7.17	8	<i>p</i> <0.05 (saline & tolt 3)




Fig. 2b. Percentage of number of entries into the open arms (2b) in elevated plus-maze test. (n=8)

***: *p*<0.001 compared to Saline group, by ANOVA (Tukey test), *: *p*<0.05 compared to Saline group, by ANOVA (Tukey test)

Mean ± S.E.M = Mean values ± Standard error of means

Table 2b: Percentage of number of entries into the open arms (n=8)

p<0.001 compared to Saline group, by ANOVA (Tukey test),

p<0.05 compared to Saline group, by ANOVA (Tukey test)

Mean ± S.E.M = Mean values ± Standard error of means

Drugs	Percentage of number of entries into the open arms (%) <i>Mean ± S.E.M</i>	Number of mice	p value
Saline	43.31±0.63	8	
Diaze 2 mg/kg	69.25±3.07	8	p<0.001 (saline & diaze)
Tolt 0.3 mg/kg	39.22±1.51	8	p>0.05 (saline & tolt 0.3)
Tolt 1 mg/kg	44.97±3.63	8	p>0.05 (saline & tolt 1)
Tolt 3 mg/kg	55.92±2.57	8	p<0.05 (saline & tolt 3)

3.3 Passive Avoidance Test

There was no significant difference in first day latency between the groups. The second day latency (retention latency) significantly differed between the groups [F (5,47)=3,284, p=0,0136 (Fig. 3)]. Scopolamine significantly shortened the second day latency compared to the saline group (p<0.001). On the other hand, tolterodine (0.3, 1 and 3 mg/kg) did not significantly have any effect on latency compared the saline group. Furthermore, cognitive performance impaired with scopolamine has been significantly improved with 3 mg/kg tolterodine (p<0.05).




Fig. 3. Effects of tolterodine on latency in passive avoidance test. (n=8)

***: $p < 0.001$ compared to Saline group, by ANOVA (Tukey test), +: $p < 0.05$ compared to Scopolamine group, by ANOVA (Tukey test)
 Mean \pm S.E.M = Mean values \pm Standard error of means

Table 3: Effects of tolterodine on latency. (n=8)

$p < 0.001$ compared to Saline group, by ANOVA (Tukey test),
 $p < 0.05$ compared to scopolamine group, by ANOVA (Tukey test)
 Mean \pm S.E.M = Mean values \pm Standard error of means

Drugs	Latency (s)	Number	p value
-------	-------------	--------	---------

		of mice	
Saline	114.03±10.69	8	
Scop 0.6 mg/kg	19.96±1.69	8	p<0.001 (saline & scop)
Tolt 0.3 mg/kg	90.9±28.72	8	p>0.05 (saline & tolt 0.3)
Tolt 1 mg/kg	124.44±35.83	8	p>0.05 (saline & tolt 1)
Tolt 3 mg/kg	147.97±32.62	8	p>0.05 (saline & tolt 3)
Scop 0.6 + tolt 3 mg/kg	85.82±16.36	8	p<0.05 (scop & scop+tol 3)

3.4. Morris Water Maze Test

There was a significant difference between drug groups or their combination [One-way ANOVA post-hoc Tukey test; $F(47,5) = 12,250$; $p < 0.0001$; Fig 4] in the time spent in the target quadrant during the probe trial of the MWM test when tolterodine groups were evaluated. Tolterodine (0.3, 1 and 3 mg/kg) had no effect on the time spent in the target quadrant in naïve mice. Scopolamine (0.6 mg/kg) significantly decreased the time spent in the target quadrant ($p < 0.01$) but tolterodine (3 mg/kg) significantly prolonged the time spent in the target quadrant in scopolamine-treated mice ($p < 0.01$) (Fig. 4a).

There was a significant difference between drug groups or their combination [One-way ANOVA post-hoc Tukey's test; $F(47,5) = 18,502$; $p < 0.0001$; Fig 4b] in the mean distance to the platform in the probe trial of the MWM test when tolterodine groups were evaluated. Tolterodine (0.3, 1 and 3 mg/kg) had no effect on the mean distance to the platform in naïve mice. Scopolamine significantly increased the mean distance to the platform ($p < 0.001$). Tolterodine (3 mg/kg) significantly decreased the mean distance to the platform in scopolamine-treated mice ($p < 0.001$) (Fig. 4b).




Fig. 4a. Effect of tolterodine on the time spent in target quadrant in the probe trial of Morris water maze test. (n=8)

***: p*<0.001 compared to Saline group, by ANOVA (Tukey test),
 ++*: p*<0.01 compared to Scopolamine group, by ANOVA (Tukey test)
 Mean ± S.E.M = Mean values ± Standard error of means

Table 4a: Effects of tolterodine on time spent in target quadrant. (n=8)

p<0.001 compared to Saline group, by ANOVA (Tukey test),
p<0.01 compared to scopolamine group, by ANOVA (Tukey test)
 Mean ± S.E.M = Mean values ± Standard error of means

Drugs	Time Spent in Target Quadrant (s)	Number of mice	p value
Saline	17.75±0.49	8	
Scop 0.6 mg/kg	7.25±1.72	8	<i>p</i> <0.001 (saline & scop)
Tolt 0.3 mg/kg	23±2.81	8	<i>p</i> >0.05 (saline & tolt 0.3)
Tolt 1 mg/kg	24.5±2.19	8	<i>p</i> >0.05 (saline & tolt 1)
Tolt 3 mg/kg	24.75±1.96	8	<i>p</i> >0.05 (saline & tolt 3)
Scop 0.6 + tolt 3 mg/kg	21±1.3	8	<i>p</i> <0.01 (scop & scop+tol 3)




Fig. 4b. Effect of tolterodine on mean distance to platform in the probe trial of Morris water maze test. (n=8)

***: $p < 0.001$ compared to Saline group, by ANOVA (Tukey test),

+++ : $p < 0.001$ compared to Scopolamine group, by ANOVA (Tukey test)

Mean \pm S.E.M = Mean values \pm Standard error of means

Table 4b: Effects of tolterodine on mean distance to platform (n=8)

$p < 0.001$ compared to Saline group, by ANOVA (Tukey test),

$p < 0.01$ compared to scopolamine group, by ANOVA (Tukey test)

Mean \pm S.E.M = Mean values \pm Standard error of means

Drugs	Mean distance to platform (cm)	Number of mice	p value
Saline	42.37 \pm 0.53	8	
Scop 0.6 mg/kg	56.62 \pm 2.05	8	$p < 0.001$ (saline & scop)
Tolt 0.3 mg/kg	41.875 \pm 1.125	8	$p > 0.05$ (saline & tolt 0.3)
Tolt 1 mg/kg	38.5 \pm 1.50	8	$p > 0.05$ (saline & tolt 1)
Tolt 3 mg/kg	37.75 \pm 2.22	8	$p > 0.05$ (saline & tolt 3)
Scop 0.6 + tolt 3 mg/kg	42.375 \pm 1.51	8	$p < 0.01$ (scop & scop+tol 3)

3.5 Effects of drugs on locomotor activity in the open field test

The influence of all the above treatments on the locomotor activity was concurrently evaluated. Neither tolterodine (0.3, 1 and 3 mg/kg) nor other drugs modified the total distance traveled [$F(63,7)=0,5777$; $p>0,05$ Fig. 5] in the open field test.




Fig. 5. Effect of drugs on total distance traveled in locomotor activity test. (n=8)

Mean ± S.E.M = Mean values ± Standard error of means

Table 5: Effects of tolterodine on distance travelled (n=8)
p<0.001 compared to Saline group, by ANOVA (Tukey test),
p<0.01 compared to scopolamine group, by ANOVA (Tukey test)
 Mean ± S.E.M = Mean values ± Standard error of means

Drugs	Distance Travelled (cm)	Number of mice	p value
Saline	1512.62±107.28	8	
Imip 30 mg/kg	1549.12±121.34	8	<i>p</i> >0.05 (saline & imip 30)
Diaze 2 mg/kg	1469±111.03	8	<i>p</i> >0.05 (saline & diaze 2)
Scop 0.6 mg/kg	1456±102.85	8	<i>p</i> >0.05 (saline & scop 0.6)
Tolt 0.3 mg/kg	1692.25±65.33	8	<i>p</i> >0.05 (saline & tolt 0.3)
Tolt 1 mg/kg	1598.87±89.96	8	<i>p</i> >0.05 (saline & tolt 1)
Tolt 3 mg/kg	1501.25±144.66	8	<i>p</i> >0.05 (saline & tolt 3)
Scop 0.6 + tolt 3 mg/kg	1611,37±86.65	8	<i>p</i> >0.05 (saline & scop+tol 3)

3. DISCUSSION

OAB is mostly characterized by urgent urinary symptoms that can cause frequent urination, nocturia, and sometimes urinary incontinence [15]. These symptoms greatly impair the person's daily life activities such as sexual function, working life, sleep patterns, and sports activities [16]. Many previous studies have shown that there is a relationship between OAB and depression [17]. It has been observed that the frequency of OAB symptoms such as urge incontinence and nocturia is increased in individuals with high levels of anxiety and depression [18]. The opposite is also true. Especially in patients with urge incontinence, the frequency of depression was found to be higher [19]. It has been understood that fatigue in patients whose sleep is interrupted due to nocturia also predisposes them to depression [20].

The aim of the pharmacological treatment of OAB is primarily to prevent excessive and involuntary contraction of the detrusor [21]. There are 5 types of muscarinic receptors in human bladder smooth muscle, the M2 and M3 receptors being the most abundant [22]. By blocking these muscarinic receptors, it is aimed to prevent excessive and frequent contraction of the detrusor [23]. The first bladder-selective anticholinergic agent developed for the treatment of OAB is tolterodine. Tolterodine is bladder-selective and not selective for any of the 5 muscarinic receptor subtypes. Many in vivo or in vitro experiments have shown that the degree of inhibition of detrusor contraction by tolterodine is much greater than the degree of inhibition of the salivary gland [24]. It produces less dry mouth compared to other anticholinergic drugs, making it an antimuscarinic agent with a higher safety profile than others [25,26].

Tolterodine is metabolized in the liver and its active metabolite is 5 hydroxymethyl. Most of the anticholinergic agents cross the blood-brain barrier and bind to muscarinic receptors in the brain, thus causing dysfunction in the central nervous system [27].

The Forced Swimming Test (FST) is one of the tests we use to determine the level of depression. We use imipramine as a positive control in this test. Imipramine reduces immobility time due to its antidepressant effect. In our study, imipramine and tolterodine (0.3, 1 and 3 mg/kg) significantly shortened the immobility time compared to the saline group. This shows that tolterodine has an antidepressant effect like imipramine. Also, in previous studies they are reported that muscarinic M1 and M2 receptor antagonists showed antidepressant-like effect in animal models in FST [28,29].

Elevated Plus-Maze (EPM) Test is also used to determine the level of anxiety, just like the FST. We use diazepam as a positive control in this test. Diazepam increases the time spent outdoors by decreasing the level of anxiety in rats. In our study, while Tolterodine did not show any effect at the dose of 0.3 mg/kg, it increased the number of transitions to the open area and the time spent in the open area compared to the saline group at 1 mg/kg and 3mg/kg doses. So, tolterodine showed anxiolytic effect like diazepam. In a previous study, muscarinic receptor antagonist such as cyamemazine demonstrated anxiolytic-like activity in the light/dark exploration test [30].

Passive Avoidance (PA) test (in other words, inhibitory avoidance) is one of the simplest and cheapest methods to evaluate learning and memory levels in experimental animals. We use it as a negative control in this test, as scopolamine impairs learning. Compared to the saline group, tolterodine had no effect on the latency period, while tolterodine used at a dose of 3 mg/kg improved the cognitive function impaired by scopolamine. Similarly, in their study, Cappon et al. showed that tolterodine alone did not affect learning and memory levels [31]. Therefore, in the treatment of overactive bladder in diseases such as Alzheimer's, it may be a good alternative to tolterodine as it does not affect cognitive function [32].

The M2 receptors are prevalent in the cortex, basal forebrain, hippocampus, and striatum [33,34,35]. In a previous study they suggested that selective M2 receptor antagonists may be beneficial for cognition [33]. And also in another study, M3 antagonism does not impair cognitive function [36]. Both scopolamine and tolterodine are anticholinergic. However; when tolterodine blocks M2 auto receptors, acetylcholine release increases and it may improve memory by reversing the acetylcholine-reducing and accordingly memory-impairing effect of scopolamine.

Morris Water Maze (MWM) test is used to evaluate memory level in experimental animals. As in the passive avoidance test, we use scopolamine as a negative control in this test. Tolterodine (0.3, 1 and 3 mg/kg) had no effect on time spent in the target quadrant in naive mice. Scopolamine (0.6 mg/kg) significantly reduced time spent in the target quadrant ($s < 0.01$), but tolterodine (3 mg/kg) significantly prolonged time spent in the target quadrant ($s < 0.01$) in scopolamine-treated mice. Tolterodine (0.3, 1 and 3 mg/kg) had no effect on the mean distance to the platform in naive mice. Scopolamine significantly increased the mean distance to the platform ($s < 0.001$). Tolterodine (3 mg/kg) significantly reduced the mean distance to the platform in scopolamine-treated mice ($p < 0.001$). An anticholinergic drug scopolamine impairs memory via acetylcholine-reducing effect. But, tolterodine blocks M2 autoreceptors, acetylcholine release increases and this may improve memory.

Open field test is used to evaluate locomotor activity in experimental animals. In this study, neither the other drugs nor the doses of tolterodine had an effect on the total distance traveled by the mice.

4. CONCLUSION

In conclusion, tolterodine prevented experimentally induced depression and anxiety, improved memory and learning of naive animals, and reversed memory and learning impairment with scopolamine. Further preclinical and clinical studies with tolterodine should be done to support all these hypothesis that in the future patients with OAB who need antidepressant and anxiolytic therapy may be treated with single drug instead of more than one drug. We think that the use of tolterodine can reduce the use of antidepressants and anxiolytics, and thus, the use of low-dose antidepressants and anxiolytics can reduce the side effects of these drugs. More preclinical and clinical studies with tolterodine should be conducted to support all these hypotheses.

Mehmet Hanifi Tanyeri: No Conflict of Interest
Mehmet Emin Buyukokuroglu: No Conflict of Interest
Pelin Tanyeri: No Conflict of Interest
Oguz Mutlu: No Conflict of Interest
Rumeysa Keles Kaya: No Conflict of Interest
Aykut Ozturk: No Conflict of Interest
Seyma Nur Basarir Bozkurt: No Conflict of Interest
Dilara Ormanci: No Conflict of Interest

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Scarneciu I, Lupu S, Bratu OG, Teodorescu A, Maxim LS, Brinza A, Laculiceanu AG, Rotaru RM, Lupu AM, Scarneciu CC. Overactive bladder: A review and update. *Exp Ther Med.* 2021; 22(6):1444. doi: 10.3892/etm.2021.10879
2. Yoshitaka A, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. *Nat Rev Dis Primers.* 2017;3: 17042. doi: 10.1038/nrdp.2017.42
3. Jacques Corcos, Mikolaj Przydacz, Lysanne Campeau, Jonathan Witten, Duane Hickling, Christiane Honeine, Sidney B. Radomski, Lynn Stothers, Adrian Wagg. CUA guideline on adult overactive bladder. *Can Urol Assoc J.* 2017;11(5):142–173. doi: 10.5489/cuaj.4586
4. Scott Martin Vouri, Clark D. Kebodeaux, Paul M. Stranges, Besu F. Teshome. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive

bladder in older adults: a systematic review and meta-analysis. *Arch Gerontol Geriatr.* 2017; 69: 77–96. doi: 10.1016/j.archger.2016.11.006

5. William C. de Groat, Derek Griffiths, Naoki Yoshimura Neural Control of the Lower Urinary Tract. *Compr Physiol.* 2015 Jan; 5(1): 327–396. doi: 10.1002/cphy.c130056

6. Ondrej Soukup, Michael Winder, Uday Kumar Killi, Vladimir Wsol, Daniel Jun, Kamil Kuca, Gunnar Tobin. Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors-Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. *Curr Neuropharmacol.* 2017 May; 15(4): 637–653. doi: 10.2174/1570159X14666160607212615

7. Susheel Vijayraghavan, Stefan Everling. Neuromodulation of Persistent Activity and Working Memory Circuitry in Primate Prefrontal Cortex by Muscarinic Receptors. *Front Neural Circuits.* 2021;15:648624. doi: 10.3389/fncir.2021.648624

8. Annette Ehrhardt, Bin Wang, Andrew C. Yung, Yanni Wang, Piotr Kozłowski, Cornelis van Breemen, John W. Schrader. Urinary Retention, Incontinence, and Dysregulation of Muscarinic Receptors in Male Mice Lacking Mras. *PLoS One.* 2015; 10(10): e0141493. doi: 10.1371/journal.pone.0141493

9. Nicola Solari, Balázs Hangya. Cholinergic modulation of spatial learning, memory and navigation. *Eur J Neurosci.* 2018 Sep; 48(5): 2199–2230. Published online 2018 Aug 19. doi: 10.1111/ejn.14089

10. Joshua A. Cohn, Elizabeth T. Brown, W. Stuart Reynolds, Melissa R. Kaufman, Douglas F. Milam, Roger R. Dmochowski. An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. *Ther Adv Urol.* 2016 Apr; 8(2): 83–90.. doi: 10.1177/1756287215626312

11. Jinhong Li, Qingquan Shi, Yunjin Bai, Chunxiao Pu, Yin Tang, Haichao Yuan, Yunjian Wu, Qiang Wei, Ping Han. Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms. *Sci Rep.* 2014; 4: 3948. doi: 10.1038/srep03948

12. Mauro Gacci, Giacomo Novara, Cosimo De Nunzio, Andrea Tubaro, Riccardo Schiavina, Eugenio Brunocilla, Arcangelo Sebastianelli, Matteo Salvi, Matthias Oelke, Stavros Gravas, Marco Carini, Sergio Serni. Tolterodine extended release in the treatment of male oab/storage luts: a systematic review. *BMC Urol.* 2014; 14: 84. doi: 10.1186/1471-2490-14-84

13. Tanyeri P, Buyukokuroglu ME, Mutlu O, Ulak G, Akar FY, Celikyurt IK, Erden BF. Evidence that the anxiolytic-like effects of the beta3 receptor agonist Amibegron involve serotonergic receptor activity. *Pharmacol Biochem Behav.* 2013;110:27-32. DOI: 10.1016/j.pbb.2013.05.017

14. Tanyeri P, Buyukokuroglu ME, Mutlu O, Ulak G, Akar FY, Celikyurt IK, Erden BF. Involvement of serotonin receptor subtypes in the antidepressant-like effect of beta receptor agonist Amibegron (SR 58611A): an experimental study. *Pharmacol Biochem Behav.* 2013;105:12-16. DOI: 10.1016/j.pbb.2013.01.010

15. Alayne Markland, Haitao Chu, C. Neill Epperson, Jesse Nodora, David Shoham, Ariana Smith, Siobhan Sutcliffe, Mary Townsend, Jincheng Zhou, Tamara Bavendam, Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Occupation and lower urinary

tract symptoms in women: A rapid review and meta-analysis from the PLUS research consortium. *Neurourol Urodyn.* 2018 Nov; 37(8): 2881–2892. doi: 10.1002/nau.23806

16. Siobhan Sutcliffe, Tamara Bavendam, Charles Cain, C. Neill Epperson, Colleen M. Fitzgerald, Sheila Gahagan, Alayne D. Markland, David A. Shoham, Ariana L. Smith, Mary K. Townsend, Kyle Rudser. The Spectrum of Bladder Health: The Relationship Between Lower Urinary Tract Symptoms and Interference with Activities. *J Womens Health (Larchmt)* 2019 Jun 1; 28(6): 827–841. doi: 10.1089/jwh.2018.7364

17. Vrijens D, Drossaerts J, Koeveringe van G, Kerrebroeck van P, Os van J, Leue C. Affective symptoms and the overactive bladder – a systematic review. *J. Psychosom Res.* 2015;78(2):95-108. DOI: 10.1016/j.jpsychores.2014.11.019

18. Miluše Jurášková, Pavel Piler, Lubomír Kukla, Jan Švancara, Petra Daňsová, Lukáš Hruban, Vít Kandrnal, Hynek Pikhart. Association between Stress Urinary Incontinence and Depressive Symptoms after Birth: the Czech ELSPAC Study. *Sci Rep.* 2020; 10: 6233.. doi: 10.1038/s41598-020-62589-5

19. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU Int.* 2006;97:96-100. DOI: 10.1111/j.1464-410X.2005.05889.x

20. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. *Urology.* 2012;80(1):90-6. DOI: 10.1016/j.urology.2012.04.004

21. Karen M. Wallace, Marcus J. Drake. Overactive bladder. Version 1. F1000Res. 2015; 4: F1000 Faculty Rev-1406.

22. Wang P, Luthin GR, Ruggieri MR. Muscarinic Acetylcholine Receptor Subtypes Mediating Urinary Bladder Contractility and Coupling to GTP Binding Proteins. *J Pharmacol Exp Ther.* 1995 May; 273(2): 959–966.

23. Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. *Rev Urol.* 2002;4(suppl 4):S28–S37.

24. Naerger H, Fry CH, Nilvebrant L. Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders. *Neurourol Urodyn.* 1995;14(Pt 5):524-526.

25. Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. *Br J Urol.* 1998;81(6):801-10. DOI: 10.1046/j.1464-410x.1998.00717.x

26. Drutz H, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct.* 1999;10(5):283-9. DOI: 10.1007/s001929970003

27. Jorge López-Álvarez, Julia Sevilla-Llewellyn-Jones, Luis Agüera-Ortiz Anticholinergic Drugs in Geriatric Psychopharmacology. *Front Neurosci.* 2019; 13: 1309. doi: 10.3389/fnins.2019.01309

28. Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA, et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. *J Pharmacol Exp Ther.* 2014;351(2):448-456. DOI: 10.1124/jpet.114.216804
29. Navarria A, Wohleb ES, Voleti B, Ota KT, Dutheil S, et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. *Neurobiol Dis.* 2015;82:254-261. DOI: 10.1016/j.nbd.2015.06.012
30. Bourin M, Dailly E, Hascöet M. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. *CNS Drug Rev.* 2004;10(3):219-229. DOI: 10.1111/j.1527-3458.2004.tb00023.x
31. Cappon DG, Bush B, Newgreen D, Finch LG, Alper HR. Tolterodine does not affect memory assessed by passive-avoidance response test in mice. *Eur J Pharmacol.* 2008;579(1-3):225-228. DOI: 10.1016/j.ejphar.2007.10.063
32. Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. *Eur J Pharmacol.* 2007;557(2-3):154-158. DOI: 10.1016/j.ejphar.2006.11.054
33. Rouse ST, Edmunds MS, Yi H, Gilmor LM, Levey IA. Localization of M(2) muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus. *Neurosci Lett.* 2000;284(3):182-186. DOI: 10.1016/s0304-3940(00)01011-9
34. Zhang W, Basile SA, Gomeza J, Volpicelli AL, Levey IA, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. *J Neurosci.* 2002;22(5):1709-1717. DOI: 10.1523/JNEUROSCI.22-05-01709.2002
35. Tzavara TE, Bymaster PF, Felder CC, Wade M, Gomeza J, Wess J, McKinzie LD, Nomikos GG. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. *Mol Psychiatry.* 2003;8(7):673-679. DOI: 10.1038/sj.mp.4001270
36. Golding FJ, Wesnes AK, Leaker RB. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function. *Br J Clin Pharmacol.* 2018;84(7):1535-1543. DOI: 10.1111/bcp.13579